Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Bookman

Showing results (11-20 of 102) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
First line therapy: have we made any improvement?Michael A Bookman
Journal of the National Cancer Institute|May 21, 2014
On the road to PARPi-platinMichael A Bookman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian CancerCharlie Gourley, Michael A Bookman
JAMA Oncology|July 3, 2025
Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell CarcinomasYvette Drew, Michael A Bookman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Intraperitoneal chemotherapy: long-term outcomes revive a long-running debateMichael A Bookman, Mark F Brady
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Reply to F.M. MuggiaMichael A Bookman, Mark F Brady
The Lancet. Oncology|July 30, 2017
To promote maintenance or treatment, is that the question?Michael A Bookman, Henry C Kitchener
Gynecologic Oncology|February 27, 2010
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group studyPeter G Rose, Chunqiao Tian, Michael A Bookman
Gynecologic Oncology|April 25, 2006
Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology GroupMichael A Bookman, D Scott McMeekin, Paula M Fracasso
The New England Journal of Medicine|April 14, 2006
Intraperitoneal chemotherapy for ovarian cancerRobert F Ozols, Michael A Bookman, Robert C Young
Pageof 11

Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
First line therapy: have we made any improvement?Michael A Bookman
Journal of the National Cancer Institute|May 21, 2014
On the road to PARPi-platinMichael A Bookman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian CancerCharlie Gourley, Michael A Bookman
JAMA Oncology|July 3, 2025
Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell CarcinomasYvette Drew, Michael A Bookman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Intraperitoneal chemotherapy: long-term outcomes revive a long-running debateMichael A Bookman, Mark F Brady
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Reply to F.M. MuggiaMichael A Bookman, Mark F Brady
The Lancet. Oncology|July 30, 2017
To promote maintenance or treatment, is that the question?Michael A Bookman, Henry C Kitchener
Gynecologic Oncology|February 27, 2010
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group studyPeter G Rose, Chunqiao Tian, Michael A Bookman
Gynecologic Oncology|April 25, 2006
Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology GroupMichael A Bookman, D Scott McMeekin, Paula M Fracasso
The New England Journal of Medicine|April 14, 2006
Intraperitoneal chemotherapy for ovarian cancerRobert F Ozols, Michael A Bookman, Robert C Young
Pageof 11